News Contact Us

Zelda Therapeutics partners with German medical cannabis group

Author : Pankaj Singh | Published Date : 2018-09-04 

Australian bio-pharmaceutical company, Zelda Therapeutics Ltd. has reportedly announced a collaboration with the German medicinal cannabis group HAPA Medical. As per trusted reports, the collaboration would offer HAPA first rights for manufacturing and distributing  Zelda’s clinically validated formulations in the expanding Germany market.

An official press release by Zelda claims that HAPA is an early mover to the Germany medical cannabis market and is reportedly developing a vertically integrated business including pharmaceutical manufacturing, medical outreach, cultivation, patient education and distribution to medical clinics and pharmacies across Germany.

Dr. Richard Hopkins, MD at Zelda Therapeutics was reportedly quoted stating that the collaboration would effectively extend the global reach of Zelda’s relationships and would further demonstrate its focus on commercializing the company’s clinically validated formulations.

The move is crucial as Germany with a population of 83 million, is predicted to be the largest single medical cannabis market in the world, Hopkins added.

As per Ricardo Pendón, HAPA’s Managing Director, the firm is pleased with the collaboration with Zelda as it is recognized as one of the world’s leading science-driven medical cannabis companies. Attaining access to Zelda’s unique product portfolio would play a significant role in HAPA’s success in the future, claims Pendón.

Reportedly, Germany is an a rather lucrative ground for Zelda given that the regional government passed a legislation in March 2017, enabling clinicians to prescribe cannabis in certain circumstances. However, self-cultivation and recreational use of cannabis is still sternly prohibited in Germany, cite sources.

As per an official statement under the German regulatory framework, patients that are registered with their insurer will reportedly be offered full reimbursement on the cost of cannabis related medicines.

Sources on this matter also claim that the legally subsidized nature of the cannabis medicine industry in Germany has led to a catalyzed growth in the number of patients with figures that have far exceeded the initial predictions.

About Author

Pankaj Singh

Pankaj Singh

Endowed with a post graduate degree in management and finance, Pankaj Singh has been a part of the online content domain for quite a while. Having worked previously as a U.K. insurance underwriter for two years, he now writes articles for fractovia.org and other online portals. He can be contacted at- [email protected] | https://twitter.com/PankajSingh2605

Related News

Cipla launches generic version of Remdesivir at a price of ₹4,000

Published Date: 2020-07-10         Author: Pankaj Singh

Cipla Limited, the multinational pharmaceutical company, has reportedly launched a generic version of the remdesivir drug (Cipremi) at a price of ?4,000 per 100 mg vial, making it among the least priced COVID-19 treatment available across the globe. According to sources familiar with the knowledg... Read More

Revival in UK hotel bookings after COVID-19 downturn, says Premier Inn

Published Date: 2020-07-09         Author: Pankaj Singh

UK has registered a revival in hotel bookings for conventional regional tourist destinations as people have started planning summer trips to the seaside and countryside, stated Premier Inn owner. The Chief Executive of Whitbread, Alison Brittain, has stated that larger cities like London continue... Read More

Fujitsu gravitates toward 'new normal' with new office working style

Published Date: 2020-07-08         Author: Pankaj Singh

Fujitsu Limited, a Japanese multinational IT company headquartered in Tokyo, has reportedly announced that it will boost its shift to becoming a digital transformation organization with an ambitious plan to transform the working style for its employees in Japan in the light of COVID-19 pandemic. ... Read More

© 2020 Fractovia. All Rights Reserved